PMID- 11112416
OWN - NLM
STAT- MEDLINE
DCOM- 20010118
LR  - 20220330
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 279
IP  - 1
DP  - 2000 Dec 9
TI  - 17 beta-estradiol inhibits tumor necrosis factor-alpha-induced nuclear 
      factor-kappa B activation by increasing nuclear factor-kappa B p105 level in 
      MCF-7 breast cancer cells.
PG  - 47-52
AB  - Tumor necrosis factor-alpha (TNF-alpha) exerts many cytological effects on a wide 
      range of cells. TNF-alpha can activate nuclear factor-kappa B (NF-kappa B). 
      Activation of NF-kappa B by TNF-alpha mediates many functions of TNF-alpha. The 
      NF-kappa B inhibitor, I kappa B alpha, negatively regulates the activity of 
      NF-kappa B. In MCF-7 cells (an estrogen and TNF-alpha receptor positive cell 
      line), treatment with 17 beta-estradiol (E(2)) inhibited TNF-alpha-induced 
      NF-kappa B DNA binding activity in the gel retardation assays. But, the level of 
      the I kappa B alpha and the TNF-alpha receptor, TNF-R1, were not obviously 
      affected. The NF-kappa B precursor, NF-kappa B p105, has been shown to be 
      associated with NF-kappa B in the cytoplasm and efficiently blocks its nuclear 
      translocation and activation. Treatment of MCF-7 cells with E(2) increased the 
      level of NF-kappa B p105 protein. The anti-estrogen, 4OH-tamoxifen, treatment 
      inhibited E(2)-induced NF-kappa B p105 expression. Our findings indicate that 
      NF-kappa B p105 plays a role in modulating the functions of TNF-alpha in the 
      estrogen receptor positive breast cancer cells.
CI  - Copyright 2000 Academic Press.
FAU - Hsu, S M
AU  - Hsu SM
AD  - Department of Pathology, College of Medicine, National Taiwan University, 
      Republic of China.
FAU - Chen, Y C
AU  - Chen YC
FAU - Jiang, M C
AU  - Jiang MC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Antigens, CD)
RN  - 0 (DNA Primers)
RN  - 0 (NF-kappa B)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 17197F0KYM (afimoxifene)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Antigens, CD/metabolism
MH  - Base Sequence
MH  - Breast Neoplasms/*metabolism/pathology
MH  - DNA Primers
MH  - Estradiol/*pharmacology
MH  - Humans
MH  - Hydrolysis
MH  - NF-kappa B/*metabolism
MH  - Protein Transport
MH  - Receptors, Tumor Necrosis Factor/metabolism
MH  - Receptors, Tumor Necrosis Factor, Type I
MH  - Tamoxifen/*analogs & derivatives/pharmacology
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/pharmacology
EDAT- 2000/12/09 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/12/09 11:00
PHST- 2000/12/09 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/12/09 11:00 [entrez]
AID - S0006-291X(00)93891-9 [pii]
AID - 10.1006/bbrc.2000.3891 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2000 Dec 9;279(1):47-52. doi: 10.1006/bbrc.2000.3891.